One article demonstrated the non-psychoactive reagent in cannabis (CBD) can significantly reduce the lung damage induced by cytokine storms
Innocan Pharma Corporation () (FRA:IP4) announced Friday the recent publication of two scientific articles supporting its approach of using CBD-Loaded Exosomes (CLX) for the treatment of COVID-19.
The company said the first paper entitled "Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients", was published in the Journal of Stem Cell Research & Therapy on October 15. It outlined that mesenchymal stem cells (MSCs) and their exosomes have potential therapeutic functions in the handling of COVID-19.
Specifically, Innocan said the study demonstrated that exosomes have the ability to enhance alveolar fluid clearance and promote epithelial and endothelial recovery through secretion of protective factors.
READ: Innocan Pharma's cosmetic clinical study indicates 90% wrinkle reduction in volunteers using SHIR Premium CBD Facial Serum
The second paper entitled "Cannabidiol (CBD) modulation of apelin in acute respiratory distress syndrome" was published in the Journal of Cellular and Molecular Medicine on October 15.
It demonstrated that the non-psychoactive reagent in cannabis (CBD) can significantly reduce the lung damage induced by cytokine storms (which is a physiological reaction in humans and other animals in which the innate immune system causes an uncontrolled and excessive release of pro-inflammatory signaling molecules called cytokines) caused by COVID-19.
The company said that Innocan Israel, a wholly-owned subsidiary, together with Tel Aviv University Professor Daniel Offen and his team, are developing a revolutionary combined therapy using MSC-driven Exosome-based loaded with CBD. The new combination is designed to target COVID-19 and neurodegenerative diseases.
Innocan said that through their potential synergistic anti-inflammatory effect, CBD-Loaded Exosomes hold the potential of helping the body fight against the COVID-19 virus's direct damage and its cytokine storm. This product is planned to act as a "guided missile" to the infected tissues, as the Exosomes migrate to Inflamed zones that are carrying CBD.
"The potential synergistic effect of CBD and Exosomes is of great potential for COVID-19 and other diseases known for local inflammation that causes destruction,” Offen said in a statement. “We are doing our best efforts to accelerate the development and to potentially offer a new approach for the COVID-19 treatment."
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham
